Skip to content

Study · Non-randomized trial · n = 12 · 1988

7 results

Insulin/C-peptide response to intravenous glucagon. A dose-response study in normal and non-insulin-dependent diabetic subjects.

Snorgaard O, Hasselstrøm K, Lumholtz IB, Thorsteinsson B, Siersbaek-Nielsen K

Acta endocrinologica1 Jan 1988Cited by 3 (Europe PMC)

PMID3289292 (opens in a new tab)PepBankPUB-03289292
Publisher pageAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In normal and non-insulin-dependent diabetic subjects, glucagon dose showed a well-defined relationship with the C-peptide response.

    In plain wordsIn normal and diabetic subjects, the C-peptide response showed a clear relationship with glucagon dose.

    Peptide
    Glucagon
    Outcome
    Direction not reportedC-peptide dose-response relationship
    Study

    n = 12

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Source sentences

    Summary
    A well defined relationship between glucagon dose and the C-peptide/insulin response was observed in both groups.
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.
  2. 02HumanNon-randomized trialActivity measurement

    In normal and non-insulin-dependent diabetic subjects, glucagon dose showed a well-defined relationship with the insulin response.

    In plain wordsIn normal and diabetic subjects, the insulin response showed a clear relationship with glucagon dose.

    Peptide
    Glucagon
    Outcome
    Direction not reportedInsulin dose-response relationship
    Study

    n = 12

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Source sentences

    Summary
    A well defined relationship between glucagon dose and the C-peptide/insulin response was observed in both groups.
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.
  3. 03HumanNon-randomized trialActivity measurement

    In non-insulin-dependent diabetic subjects, glucagon dose-response curves differed significantly from those in normal subjects.

    In plain wordsIn diabetic subjects, responses across glucagon doses differed from those in normal subjects.

    Peptide
    Glucagon
    Outcome
    Direction not reportedDose-response curve course
    Study

    n = 12

    Comparator
    Normal subjects
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Source sentences

    Summary
    The course of the dose-response curves was significantly different in diabetics.
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.
  4. 04HumanNon-randomized trialActivity measurement

    In non-insulin-dependent diabetic subjects, maximal C-peptide response to glucagon was 53% of normal subjects' response (P = 0.037).

    In plain wordsIn diabetic subjects, the maximum C-peptide response to glucagon was lower than in normal subjects.

    Peptide
    Glucagon
    Outcome
    DecreaseMaximal C-peptide response
    Study

    n = 12

    Comparator
    Normal subjects
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Measurements

    Maximal C-peptide response
    53%
    relative to normal subjects
    P value
    0.037
    diabetic versus normal

    Source sentences

    Summary
    The maximal obtainable C-peptide response (E-max) was reduced to 53% of the response in normal subjects (P = 0.037), and the insulin response was reduced to 52% (P = 0.014).
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.
  5. 05HumanNon-randomized trialActivity measurement

    In non-insulin-dependent diabetic subjects, maximal insulin response to glucagon was 52% of normal subjects' response (P = 0.014).

    In plain wordsIn diabetic subjects, the maximum insulin response to glucagon was lower than in normal subjects.

    Peptide
    Glucagon
    Outcome
    DecreaseMaximal insulin response
    Study

    n = 12

    Comparator
    Normal subjects
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Measurements

    Maximal insulin response
    52%
    relative to normal subjects
    P value
    0.014
    diabetic versus normal

    Source sentences

    Summary
    The maximal obtainable C-peptide response (E-max) was reduced to 53% of the response in normal subjects (P = 0.037), and the insulin response was reduced to 52% (P = 0.014).
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.
  6. 06HumanNon-randomized trialActivity measurement

    In diabetic subjects, glucagon reached maximal response at 10 micrograms/kg, while normal subjects appeared to require higher doses.

    In plain wordsIn diabetic subjects, maximum response occurred at a lower glucagon dose than normal subjects appeared to need.

    Peptide
    Glucagon
    Outcome
    DecreaseDose reaching maximal response
    Study

    n = 12

    Comparator
    Normal subjects
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Measurements

    Dose reaching maximal response
    10 micrograms/kg
    diabetic subjects

    Source sentences

    Summary
    E-max was reached in diabetics with only 10 micrograms/kg of glucagon, whereas higher doses seem to be needed in the control group.
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.
  7. 07HumanNon-randomized trialActivity measurement

    In diabetic subjects, the glucagon dose producing half-maximal response was not significantly higher than in normal subjects.

    In plain wordsIn diabetic subjects, the glucagon dose for half-maximal response was not significantly higher than in normal subjects.

    Peptide
    Glucagon
    Outcome
    No significant changeDose producing half-maximal response
    Study

    n = 12

    Comparator
    Normal subjects
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1, 2, 5, 10 micrograms/kg; 1 mg only in diabetics · intravenousAs given in this study (human).

    Source sentences

    Summary
    However, the glucagon dose causing 50% of E-max (ED50) was not significantly higher.
    1 context sentence
    Summary · context
    The C-peptide and insulin secretory responses to increasing doses of iv glucagon (1, 2, 5, 10 micrograms/kg body weight and 1 mg (only diabetics] were investigated in six lean non-insulin-dependent diabetic patients and six normal subjects, matched for body weight and fasting blood glucose concentrations.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.